Black Diamond Therapeutics, Inc. (BDTX) Tops Q1 EPS by 93c

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) reported Q1 EPS of $0.98, $0.93 better than the analyst estimate of $0.05. Revenue for the quarter came in at $70 million versus the consensus estimate of $28 million.

For earnings history and earnings-related data on Black Diamond Therapeutics, Inc. (BDTX) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results